Global Rotavirus Prophylaxis Market – Industry Trends and Forecast to 2029

Global Rotavirus Prophylaxis Market, By Treatment (Rotarix, Rotavac, Rotavin-M1, Lanzhou Lamb, Oral Rehydration Fluid, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Market Analysis and Size

In recent years, the rotavirus prophylaxis market is anticipated to grow rapidly during the forecast period. Rotavirus is a virus that easily infects children and newborns. Severe watery diarrhoea, fever, vomiting, and abdominal pain are all symptoms of the infection. Within five years of birth, practically all children in the United States have at least one rotavirus infection; over 400,000 children are sent to doctors for treatment; and approximately 50–60 children die each year.

Data Bridge Market Research analyses that the rotavirus prophylaxis market was valued at USD 7.415 billion in 2021 and is expected to reach USD 15.66 billion by 2029, registering a CAGR of 9.80% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Rotavirus is a vaccine-preventable virus from the reoviridae family that causes diarrhoea and dehydration. It is spread through infected individuals or contaminated surfaces. Fever and vomiting are the first signs and symptoms that patients with rotavirus infections experience. Even though rotavirus infections are unpleasant, you can typically treat them at home by drinking plenty of water to avoid dehydration. Severe dehydration may need injecting fluids intravenously in the hospital.

Report Scope and Market Segmentation

Rotavirus Prophylaxis Market Dynamics

Drivers

• Increasing prevalence of rotavirus infection

The rising prevalence of rotavirus infection is anticipated to propel the rotavirus prophylaxis market's growth rate. Because of their poor hygiene habits, rotavirus sickness is highly contagious and spreads quickly among children. In hospitals as well as day-care centres, rotavirus infection is a widespread healthcare issue. Another factor driving the rotavirus vaccine market is support from UNICEF and GAVI (a vaccine alliance of multiple countries under which 45 countries have been approved for rotavirus vaccine support) for large-scale vaccination, supply availability, and access to affordable prices.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of rotavirus prophylaxis market is the rising healthcare expenditure which helps in improving its infrastructure.  

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the rotavirus prophylaxis market. Additionally, high disposable income and continuously changing lifestyle pf people will result in the expansion of rotavirus prophylaxis market. Along with this, favourable government policies are estimated to enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the rotavirus prophylaxis market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising demand for vaccine and an increase in the number of emerging markets will further provide beneficial opportunities for the rotavirus prophylaxis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the rotavirus prophylaxis market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This rotavirus prophylaxis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rotavirus prophylaxis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Rotavirus prophylaxis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Rotavirus Prophylaxis Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world were severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations had a negative impact on the market of rotavirus prophylaxis.

Global Rotavirus Prophylaxis market Scope

The rotavirus prophylaxis market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Rotarix
• Rotavac
• Rotavin-M1
• Lanzhou Lamb
• Oral Rehydration Fluid
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Rotavirus Prophylaxis Market Regional Analysis/Insights

The Rotavirus prophylaxis market is analysed and market size insights and trends are provided by country, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Rotavirus prophylaxis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the rotavirus prophylaxis market because of the growing prevalence of rotavirus and surging demand for disease-specific treatment. Additionally, presence of well-established healthcare infrastructure and growing awareness among patients will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to the increasing number of generic manufacturers and rising healthcare expenditure in this region. Furthermore, growing level of disposable income will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Rotavirus Prophylaxis Market Share Analysis

The Rotavirus prophylaxis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to rotavirus prophylaxis market.

Some of the major players operating in the rotavirus prophylaxis market are:

• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (US)
• Bharat Serums and Vaccines Limited (India)
• Bharat Biotech (India)
• QIMR Berghofer Medical Research Institute (Australia)
• Serum Institute of India Pvt. Ltd. (India)
• Biological E Limited (India)
• Bio Farma (Indonesia)
• Astellas Pharma Inc. (Japan)
• CSL Limited (Australia)
• Johnson & Johnson Private Limited (US)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• AstraZeneca (UK)